TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03279289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 4 mg/kg administered intravenous infusion on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 4 mg/kg administered intravenous infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid (dl racemic)
Description: 400 mg/m2 intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid (dl racemic)
Description: 400 mg/m2 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 400 mg/m2 intravenous bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: 400 mg/m2 intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m2 continuous intravenous infusion over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m2 continuous intravenous infusion over 46 hours
Study: NCT01872325

Intervention type: BEHAVIORAL
Intervention: Education
Description: An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
Study: NCT03865888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: Cyclosporins eye drops to be administered in dry eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus eye drops to be administered in dry eyes
Study: NCT01128764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for depression and healthy lifestyle plus exercise
Description: CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
Study: NCT00576979

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study: NCT01128764

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for depression
Description: Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
Study: NCT02864901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSL-W
Description: Plaque reducing gum
Study: NCT00576979

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy
Study: NCT00946166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
Study: NCT00576979

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy
Study: NCT02864901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chewing Gum Placebo
Study: NCT00576979

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy
Study: NCT04213651

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT03375853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Based Response Training Weight Loss Intervention
Description: Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Response Training Control Intervention
Description: Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
Study: NCT06056947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVEGYN A
Description: EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVEGYN B
Description: EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gynomax® XL Vaginal Ovule
Description: 200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
Study: NCT02224898

Intervention type: BEHAVIORAL
Intervention: Mobile Mindfulness Therapy
Description: Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.

Intervention type: BEHAVIORAL
Intervention: Mobile Mindfulness Therapy
Description: Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
Study: NCT01203657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi classes, 60 minutes, 2x week
Study: NCT04756414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure based face-to-face Cognitive Behavior Group Therapy
Description: See under detailed description
Study: NCT01646099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based sun protection education
Description: Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
Study: NCT00501228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mg/kg ID Once Daily x 1 Week
Study: NCT00880360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak
Description: Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
Study: NCT00888667

Intervention type: OTHER
Intervention: Pacing interventions
Description: 10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
Study: NCT00521781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg p.o. daily starts week 36 of initiating Abraxane.
Study: NCT02048345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension Fasted State
Study: NCT02479503

Intervention type: PROCEDURE
Intervention: Antibiotic prophylaxis in adult heart transplantation
Study: NCT00540020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Study: NCT02048345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension Fed State

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution Fasted State

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution Fed State
Study: NCT01412853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR-Spectroscopy
Description: response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
Study: NCT02091180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline infusion
Study: NCT01405092

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: use of continuous renal replacement machine for renal replacement
Description: usual care with volume removal during continuous renal replacement therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of continuous renal replacement machine for renal replacement
Description: usual care with volume removal during continuous renal replacement therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal
Description: blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
Study: NCT01393977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation of limb function
Description: only receive rehabilitation of limb function

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Transplantation
Description: mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
Study: NCT00460980

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual reality laparoscopic simulator training
Description: The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
Study: NCT02538172

Intervention type: OTHER
Group type: OTHER
Intervention: T-Track® CMV assay

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-Track® CMV assay
Study: NCT01701622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks.
Study: NCT03775837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Ginseng C.A. Mey Extract group
Description: This group takes Panax Ginseng C.A. Mey Extract for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes placebo for 8 weeks
Study: NCT03335540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor
Description: Specified dose on specified day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Specified dose on specified day
Study: NCT02867397

Intervention type: DRUG
Group type: OTHER
Intervention: Teysuno (S1) in combination with epirubicin and oxaliplatin
Study: NCT04217369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabits Predictions
Description: Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
Study: NCT01139034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-designed surface functional electrical stimulator
Description: Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
Study: NCT00728065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White Bread
Description: About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White Bread
Description: About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White bread with added 7.32g Salvia hispanica
Description: About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White bread with added 15.58g Salvia hispanica
Description: About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
Study: NCT00260039

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Gardasil
Description: 0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: octavalent HPV Vaccine - dose formulation 1
Description: 0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: octavalent HPV Vaccine - dose formulation 2
Description: 0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: octavalent HPV Vaccine - dose formulation 3
Description: 0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
Study: NCT01292720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in matching volumes
Study: NCT00318461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg for s.c. (under the skin) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1.5-2.0 g tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1.5-2.0 g tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1.5-2.0 g tablets
Study: NCT00728065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White bread with added Salvia hispanica
Description: About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice milk
Description: Rice milk containing 50g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice milk
Description: Rice milk containing 50g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched rice milk containing 7.32g Salvia hispanica
Description: Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched rice milk containing 15.58g Salvia hispanica
Description: Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched rice milk containing 24g Salvia hispanica
Description: Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
Study: NCT01271140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
Study: NCT02195492

Intervention type: DRUG
Intervention: Synvisc®
Study: NCT00914381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy
Study: NCT02718859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation (IRE )
Description: The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: irreversible electroporation (IRE )
Description: The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
Study: NCT02906254

Intervention type: OTHER
Intervention: ECIL-4 guidelines group
Description: Antibiotics were stopped when patients had been afebrile for more than 48 hours

Intervention type: OTHER
Intervention: ECIL-4 guidelines group
Description: Antibiotics were stopped when patients had been afebrile for more than 48 hours

Intervention type: OTHER
Intervention: Short-course antibiotic therapy
Description: Antibiotics were stopped on day 5 in febrile or afebrile patients
Study: NCT03172689

Intervention type: DEVICE
Group type: OTHER
Intervention: CardioQ
Description: comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
Study: NCT00318461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1.5-2.0 g tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1.5-2.0 g tablets
Study: NCT02673229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Santyl
Description: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bacitracin
Description: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
Study: NCT01710930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of predictive factors
Description: Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9).